Drug Safety During Maternal Thrombotic Disorders: Evidence-Based Review for Clinical Practice

Abstract

Thrombotic disorders during pregnancy present complex challenges for clinicians, requiring a nuanced understanding of maternal-fetal risks, individualized patient assessment, and safe pharmacologic interventions. This review synthesizes recent evidence and clinical guidelines regarding drug safety in the management of maternal thrombotic disorders, with a focus on epidemiology, pathophysiology, risk stratification, diagnostic approaches, and therapeutic strategies. Emphasis is placed on balancing efficacy, safety, and fetal considerations, while highlighting emerging therapies and practical clinical implications for optimal maternal and neonatal outcomes.

Introduction

Maternal thrombotic disorders, encompassing venous thromboembolism (VTE) and arterial thrombosis, are among the leading causes of morbidity and mortality in pregnancy. The prothrombotic milieu of gestation, coupled with physiological and pathological changes, necessitates vigilant risk assessment and judicious pharmacotherapy. Drug safety remains paramount due to potential teratogenicity, peripartum bleeding, and long-term fetal impacts. This article provides a comprehensive review of recent evidence and guideline-based strategies for safe drug use in maternal thrombotic disorders, tailored for physicians and healthcare professionals involved in maternal-fetal medicine.

Epidemiology / Disease Burden

Venous thromboembolism is a leading non-obstetric cause of maternal death in developed countries, with an incidence of approximately 1–2 per 1000 pregnancies. The risk of VTE increases fivefold during pregnancy and peaks in the postpartum period. Arterial thromboses, while less frequent, have significant implications for maternal and neonatal outcomes. The global burden is influenced by demographic factors, prevalence of inherited and acquired thrombophilias, and healthcare access.

Pathophysiology

Pregnancy is characterized by a physiological hypercoagulable state driven by increased levels of coagulation factors (notably factors VII, VIII, X, and fibrinogen), decreased anticoagulant activity (reduced protein S), and impaired fibrinolysis. These adaptations minimize postpartum hemorrhage risk but predispose to thromboembolic events. Additional contributors include venous stasis from uterine compression, vascular injury during delivery, and underlying thrombophilias or comorbidities such as antiphospholipid syndrome.

Risk Factors

Major risk factors for maternal thrombosis include a history of previous VTE, inherited thrombophilias (e.g., factor V Leiden, prothrombin G20210A mutation, antithrombin deficiency), acquired hypercoagulable states (antiphospholipid syndrome), obesity, advanced maternal age, immobility, cesarean delivery, and multifetal gestation. Additional risks arise from comorbidities such as preeclampsia, systemic lupus erythematosus, and malignancy.

Clinical Features

Clinical manifestations of maternal thrombotic disorders are often subtle and may overlap with common pregnancy symptoms. Deep vein thrombosis typically presents with unilateral lower limb swelling, pain, and erythema. Pulmonary embolism may manifest as dyspnea, chest pain, tachycardia, or syncope. Arterial events can cause acute neurologic deficits or limb ischemia. A high index of suspicion is essential due to atypical presentations and the need for prompt intervention.

Diagnosis

Diagnostic strategies must balance maternal and fetal safety. Compression ultrasonography is the gold standard for suspected DVT. For pulmonary embolism, ventilation-perfusion (V/Q) scanning is preferred over computed tomography pulmonary angiography (CTPA) to minimize radiation exposure, though CTPA is indicated when V/Q results are indeterminate. D-dimer levels are less specific in pregnancy, and clinical prediction rules require cautious interpretation. Laboratory evaluation for thrombophilias and antiphospholipid antibodies is indicated in selected cases.

Treatment & Management

Anticoagulation forms the cornerstone of therapy. Low molecular weight heparin (LMWH) is the preferred agent due to its predictable pharmacokinetics, efficacy, and safety profile; it does not cross the placenta and has minimal teratogenic risk. Unfractionated heparin (UFH) is reserved for patients with renal impairment or imminent delivery due to its reversibility. Vitamin K antagonists (e.g., warfarin) are contraindicated in pregnancy except for specific indications such as mechanical heart valves owing to teratogenicity, especially during the first trimester. Direct oral anticoagulants (DOACs) lack sufficient safety data and are generally avoided. Antiplatelet agents, including low-dose aspirin, are indicated in antiphospholipid syndrome and preeclampsia prevention but require careful consideration of bleeding risk. Multidisciplinary management is essential, particularly around delivery timing and anesthesia planning.

Recent Advances / Emerging Therapies

Recent research explores the safety and efficacy of novel anticoagulants and individualized dosing regimens. Extended prophylaxis with LMWH in high-risk postpartum women has demonstrated benefit. Pharmacogenomics and anti-Xa level-guided dosing may further optimize therapy. Newer agents such as fondaparinux have limited but promising data in select cases, particularly with heparin intolerance. Ongoing trials are evaluating the safety of selected DOACs in the postpartum period. Enhanced risk stratification tools incorporating biomarkers and clinical parameters are under development to refine prophylactic strategies.

Guideline Recommendations

International guidelines (e.g., American College of Obstetricians and Gynecologists, Royal College of Obstetricians and Gynaecologists, American Society of Hematology) uniformly endorse LMWH as first-line therapy for VTE in pregnancy. Warfarin is avoided except in select high-risk scenarios. Routine thrombophilia screening is not recommended for all women but is indicated after unprovoked VTE or in the presence of strong family history. Peripartum management should involve planned cessation of anticoagulation, use of regional anesthesia protocols, and resumption postpartum. Aspirin is advised for high-risk antiphospholipid syndrome and preeclampsia prevention.

Conclusion

Safe management of maternal thrombotic disorders requires evidence-based, individualized care that weighs maternal benefits against fetal risks. LMWH remains the standard of care for anticoagulation, with ongoing research into novel agents and personalized dosing. Adherence to guideline recommendations, vigilant risk assessment, and multidisciplinary collaboration are essential for optimizing outcomes. Future advances may yield further improvements in drug safety and therapeutic precision for this high-risk population.